Weekly Research Analysts’ Ratings Changes for Solventum (SOLV)

A number of firms have modified their ratings and price targets on shares of Solventum (NYSE: SOLV) recently:

• 5/15/2026 – Solventum is now covered by Wedbush. They set an “outperform” rating and a $94.00 price target on the stock.
• 5/14/2026 – Solventum was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $50.00 price target on the stock.
• 5/6/2026 – Solventum had its price target lowered by UBS Group AG from $82.00 to $78.00. They now have a “neutral” rating on the stock.
• 5/6/2026 – Solventum had its price target lowered by Stifel Nicolaus from $105.00 to $90.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Solventum had its price target raised by KeyCorp from $92.00 to $93.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Solventum had its price target lowered by Wells Fargo & Company from $83.00 to $70.00. They now have an “equal weight” rating on the stock.
• 5/6/2026 – Solventum had its “buy” rating reaffirmed by BTIG Research. They now have a $89.00 price target on the stock.
• 4/27/2026 – Solventum had its price target lowered by KeyCorp from $99.00 to $92.00. They now have an “overweight” rating on the stock.
• 4/17/2026 – Solventum had its price target lowered by Piper Sandler from $98.00 to $92.00. They now have an “overweight” rating on the stock.

Insider Activity

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.24% of the stock is currently owned by corporate insiders.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.